Click a keyword to view all the abstracts on this site tagged with that keyword.
- clinical trials and statistical methods
- clinical trials and systemic lupus erythematosus (SLE)
- clinical trials and systemic sclerosis
- clinical trials and thrombosis
- Clinical trials and tocilizumab
- clinical trials and treatment
- clinical trials and ulcers
- clinical trials and vasculitis
- clinically suspect arthralgia and inflammatory arthritis
- cluster
- CMS
- CMV
- CNS inflammation
- CNS Lupus
- CNS Lupus and autoantibodies
- CNS Lupus and immunoregulation
- CNS Lupus and Immunotherapy
- CNS Lupus and magnetic resonance imaging (MRI)
- CNS Lupus and SLE
- CNS Vasculitis
- CNS Vasculitis and spine involvement
- CNS Vasculitis and treatment
- Co-morbidities
- Co-morbidities and ankylosing spondylitis (AS)
- Co-morbidities and crystal-induced arthritis
- Co-morbidities and epidemiologic methods
- Co-morbidities and psoriatic arthritis
- Co-morbidities and rheumatoid arthritis (RA)
- Co-morbidities and systemic lupus erythematosus (SLE)
- co-stimulation
- co-stimulation and mouse model
- co-stimulation and rheumatoid arthritis (RA)
- co-stimulation and salivary gland
- co-stimulation and therapeutic targeting
- coagulation
- coagulation disorder
- coagulation disorder and juvenile SLE
- coagulation disorder and thrombosis
- coccidioidomycosis
- Cogalt1
- cognitive behavioral therapy
- cognitive behavioral therapy and prevention
- Cognitive dysfunction
- cognitive dysfunction and angiotensin
- cognitive dysfunction and clinical research
- cognitive dysfunction and depression
- Cognitive dysfunction and fibromyalgia
- cognitive dysfunction and Lupus
- cognitive dysfunction and measure
- Cognitive dysfunction and osteoarthritis
- cognitive dysfunction and quality of life
- Cognitive dysfunction and rheumatoid arthritis (RA)
- cognitive dysfunction and risk assessment
- cognitive dysfunction and stress
- Cognitive dysfunction and systemic lupus erythematosus (SLE)
- Cognitive dysfunction and uric acid
- Colchicine
- colchicine and familial Mediterranean fever
- colchicine and gout
- colchicine and price
- Collagen
- collagen and anti-TNF therapy
- collagen and fibroblasts
- collagen and fibrosis
- collagen and histone acetylation
- collagen and human leukocyte antigens (HLA)
- collagen and inflammatory arthritis
- collagen and interleukins (IL)
- collagen and osteoarthritis
- collagen and rheumatoid arthritis (RA)
- collagen and scleroderma
- collagen and systemic sclerosis
- collagen and tolerance
- collagen and treatment
- column and hedgehog
- combination therapies
- combination therapies and comparative effectiveness and harms
- combination therapies and LFN
- combination therapies and methotrexate (MTX)
- combination therapies and remission
- combination therapies and rheumatoid arthritis
- combination therapies and rheumatoid arthritis (RA)
- Communication
- communication and positive affect
- communication and quality of care
- communication and self-management
- Community programs
- community programs and exercise
- community programs and legislation
- community programs and nursing roles
- Community programs and systemic lupus erythematosus (SLE)
- Comorbidity
- comorbidity and administrative databases
- comorbidity and cluster
- comorbidity and disability
- comorbidity and drug treatment
- comorbidity and epidemiologic methods
- comorbidity and fatigue
- Comorbidity and fibromyalgia
- comorbidity and giant cell arteritis
- Comorbidity and gout
- comorbidity and hypertension
- comorbidity and incident
- Comorbidity and juvenile idiopathic arthritis (JIA)
- comorbidity and magnetic resonance imaging (MRI)
- comorbidity and malignancy
- comorbidity and osteoarthritis
- Comorbidity and psoriatic arthritis
- comorbidity and qualitative
- comorbidity and questionnaires
- comorbidity and renal disease
- comorbidity and rheumatic disease
- Comorbidity and rheumatoid arthritis (RA)
- Comorbidity and spondylarthritis
- Comorbidity and spondylarthropathy
- comorbidity and systemic lupus erythematosus (SLE)
- Comorbidity and vasculitis
- comparative effectiveness
- Comparative effectiveness and harms
- comparative effectiveness and harms and epidemiologic methods
- comparative effectiveness and harms and juvenile idiopathic arthritis (JIA)
- comparative effectiveness and harms and patient outcomes
- comparative effectiveness and harms and pediatric rheumatology
- comparative effectiveness and harms and psoriatic arthritis
- comparative effectiveness and harms and rheumatoid arthritis
- comparative effectiveness and harms and rheumatoid arthritis (RA)
- comparative effectiveness and harms and spondylarthritis
- comparative effectiveness and harms and treatment
- competency
- competency and ultrasound
- complement
- complement and anakinra
- complement and biomarkers
- complement and complement inhibitors
- complement and cryoglobulinemia
- complement and immunosuppressants
- complement and inflammation
- complement and innate immunity
- complement and interferons
- complement and longitudinal studies
- complement and nephritis
- complement and neutrophils
- complement and polymorphism
- complement and pregnancy
- complement and psoriatic arthritis
- complement and renal disease
- complement and rheumatoid arthritis (RA)
- complement and scleroderma
- complement and systemic lupus erythematosus (SLE)
- complement and thrombosis
- complement and vasculitis
- complement deficiency
- complement deficiency and genetics
- Complement deficiency and juvenile dermatomyositis
- complement deficiency and lupus nephritis
- complement deficiency and systemic lupus erythematosus (SLE)
- complement deficiency and systemic sclerosis
- complement inhibitors
- complement inhibitors and Immunotherapy
- complement inhibitors and safety
- Complementary alternative medicine
- complementary alternative medicine and patient preferences
- Complementary alternative medicine and systemic lupus erythematosus (SLE)
- complex regional pain syndrome
- Complex regional pain syndrome and disability
- Compliance
- Compliance and Disease Activity
- Compliance and DMARDs
- Compliance and gout
- Compliance and Health Assessment Questionnaire
- Compliance and laboratory tests
- Compliance and methotrexate (MTX)
- Compliance and qualitative
- Compliance and rheumatoid arthritis (RA)
- complications
- Complications and epidemiologic methods
- complications and genetic architecture
- complications and morbidity and mortality
- complications and musculoskeletal disorders
- complications and outcomes
- complications and rheumatoid arthritis (RA)
- complications and rituximab
- Complications and takayasu arteritis
- complimentary and alternative therapy
- Complimentary and alternative therapy and fibromyalgia
- complimentary and alternative therapy and osteoarthritis
- Complimentary and alternative therapy and rheumatoid arthritis (RA)
- complimentary and diagnosis
- computational and Drug Repositioning
- Computed tomography (CT)
- computed tomography (CT) and atherosclerosis
- computed tomography (CT) and autologous transplantation
- computed tomography (CT) and cardiovascular disease
- computed tomography (CT) and coronary artery disease
- computed tomography (CT) and cross-sectional studies
- computed tomography (CT) and enthesopathy
- computed tomography (CT) and gout
- computed tomography (CT) and imaging techniques
- computed tomography (CT) and inflammatory bowel disease (IBD)
- computed tomography (CT) and inflammatory myositis